Upadacitinib OverviewUpadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was approved for medical use in the United States and in the European Union in 2019, and was developed by the biotech company AbbVie. Commo...
Read more Upadacitinib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Upadacitinib
Recent Upadacitinib Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet, Extended Release: 15mg
Other drugs which contain Upadacitinib or a similar ingredient: (1 result)
- RINVOQ Upadacitinib